J-Pharma Co (TSE:520A) EBITDA Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:520A J-Pharma Co Ltd TSE:520A
9 GF Score
Price 円290.00
View Full Analysis

What is J-Pharma Co EBITDA Margin %?

J-Pharma Co TSE:520A -2.36% 9 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:520A with a GF Score™ of 9/100. Among 939 Biotechnology companies, J-Pharma Co ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. J-Pharma Co's EBITDA for the three months ended in Dec. 2025 was 円-484.57 Mil. J-Pharma Co's Revenue for the three months ended in Dec. 2025 was 円0.00 Mil. Therefore, J-Pharma Co's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

J-Pharma Co  (TSE:520A) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

J-Pharma Co EBITDA Margin % Related Terms

J-Pharma Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for J-Pharma Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J-Pharma Co EBITDA Margin % Chart

J-Pharma Co Annual Data
Trend Mar24 Mar25
EBITDA Margin %
0.00 0.00

J-Pharma Co Quarterly Data
Mar24 Mar25 Dec25
EBITDA Margin % 0.00 0.00 0.00

TSE:520A vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, J-Pharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

J-Pharma Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, J-Pharma Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where J-Pharma Co's EBITDA Margin % falls into.


TSE:520A
9GF Score
J-Pharma Co Ltd TSE:520A
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

J-Pharma Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

J-Pharma Co's EBITDA Margin % for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-1503.008/0
= %

J-Pharma Co's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-484.574/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
J-Pharma Co (TSE:520A) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on J-Pharma Co and its competitors. According to the industry distribution chart, J-Pharma Co ranks #999999 out of 939 companies in the Biotechnology industry.
Is J-Pharma Co's EBITDA Margin % too high?
J-Pharma Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, J-Pharma Co ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, J-Pharma Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does J-Pharma Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, J-Pharma Co ranks #999999 out of 939 companies for EBITDA Margin %. This places J-Pharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on J-Pharma Co and its competitors. J-Pharma Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J-Pharma Co stock overvalued right now?
J-Pharma Co (TSE:520A) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. J-Pharma Co's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For J-Pharma Co (TSE:520A), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

J-Pharma Co Business Description

Address 1-10-11, HamamatsuCho, 8th floor, Minato-Ku, Tokyo, JPN, 105-0013
J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.
9GF Score

Get the complete analysis for TSE:520A

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円290.00
Price